Maxim analyst Jason McCarthy raised the firm’s price target on Bionomics to $10 from $7 and keeps a Buy rating on the shares after the company reported that its Phase 2b ATTUNE study in PTSD met its primary endpoint with a significant reduction in PTSD symptom severity versus placebo. This initial data in PTSD “makes a compelling case for BNC210,” says the firm, which lowers its revenue risk adjustment to 60%, from 80%, which increases its price target on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNOX:
- William Blair reiterates Outperform on Bionomics after ‘significant win’
- Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
- Bionomics reports ‘positive’ results from Phase 2b ATTUNE trial of BNC210
- Bionomics provides update on Merck collaboration
- Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD